NFO Alert: Bajaj Finserv Mutual Fund launches healthcare fund

Bajaj Finserv Mutual Fund has announced the launch of its healthcare fund. Bajaj Finserv Healthcare Fund is an open-ended equity scheme that follows pharma, healthcare and allied themes.

The new fund offer or NFO of the scheme will open for subscription on December 6 and close on December 20. The scheme will reopen for continuous sale and repurchase within five business days of the allotment date.

Also Read | Taking stock: 70% equity mutual funds outperform their benchmarks in 2024


The objective is to generate long-term capital appreciation by predominantly investing in equity and equity-related securities of pharma, healthcare and allied companies.

The scheme will be benchmarked against the BSE Healthcare Total Return Index (TRI) and managed by Nimesh Chandan, Sorbh Gupta, and Siddharth Chaudhary

It will offer regular and direct plans both with growth and IDCW options. For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP) and Systematic Transfer Plan (STP), the exit load will be as follows:

• if units are redeemed / switched out within 3 months from the date of allotment, an exit load of 1% of applicable NAV will be payable.
  
• if units are redeemed/switched out after 3 months from the date of allotment, no exit load is payable.
  

The minimum application amount for lumpsum and SIP investment is Rs 500 and in multiples of Re 1 thereafter with minimum six installments for SIP investment. The maximum total expenses ratio (TER) permissible under Regulation 52 (6) (c) is up to 2.25%.

Also Read | Quant Mutual Fund expands senior management, appoints new CEO and 6 other key appointments in past 9 months

The sectoral fund will allocate 80-100% in equity and equity-related securities of pharma, healthcare and allied companies, 0-20% in equities and equity-related securities of other than pharma, healthcare and allied companies, 0-20% in debt and money market instruments and units of mutual fund schemes, and 0-10% in units issued by REITs and InvITs.

The scheme is suitable for investors seeking wealth creation over the long term and keen to invest predominantly in equity and equity -related instruments of pharma, healthcare and allied companies.

The principal invested in the scheme will be at “very high” risk according to the riskometer of the scheme.